GB0522298D0 - Agents that bind IgE - Google Patents

Agents that bind IgE

Info

Publication number
GB0522298D0
GB0522298D0 GBGB0522298.9A GB0522298A GB0522298D0 GB 0522298 D0 GB0522298 D0 GB 0522298D0 GB 0522298 A GB0522298 A GB 0522298A GB 0522298 D0 GB0522298 D0 GB 0522298D0
Authority
GB
United Kingdom
Prior art keywords
agents
bind ige
activation
ige
bind
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0522298.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natural Environmental Research Council
Original Assignee
Natural Environmental Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natural Environmental Research Council filed Critical Natural Environmental Research Council
Priority to GBGB0522298.9A priority Critical patent/GB0522298D0/en
Publication of GB0522298D0 publication Critical patent/GB0522298D0/en
Priority to US12/092,368 priority patent/US8343504B2/en
Priority to JP2008538390A priority patent/JP5123858B2/ja
Priority to PCT/GB2006/003986 priority patent/WO2007051975A2/en
Priority to EP06808355A priority patent/EP1978990B1/en
Priority to CN200680050239.3A priority patent/CN101351216B/zh
Priority to AT06808355T priority patent/ATE551065T1/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
GBGB0522298.9A 2005-11-01 2005-11-01 Agents that bind IgE Ceased GB0522298D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0522298.9A GB0522298D0 (en) 2005-11-01 2005-11-01 Agents that bind IgE
US12/092,368 US8343504B2 (en) 2005-11-01 2006-10-26 Methods of administering IGBPMA to treat type 1 hypersensitivity
JP2008538390A JP5123858B2 (ja) 2005-11-01 2006-10-26 ＩｇＥに結合する薬剤
PCT/GB2006/003986 WO2007051975A2 (en) 2005-11-01 2006-10-26 Compositions comprising igbpma and uses thereof
EP06808355A EP1978990B1 (en) 2005-11-01 2006-10-26 Compositions comprising igbpma and uses thereof
CN200680050239.3A CN101351216B (zh) 2005-11-01 2006-10-26 包含igbpma的组合物及其用途
AT06808355T ATE551065T1 (de) 2005-11-01 2006-10-26 Zusammensetzungen mit igbpma und ihre verwendungen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0522298.9A GB0522298D0 (en) 2005-11-01 2005-11-01 Agents that bind IgE

Publications (1)

Publication Number Publication Date
GB0522298D0 true GB0522298D0 (en) 2005-12-07

Family

ID=35516154

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0522298.9A Ceased GB0522298D0 (en) 2005-11-01 2005-11-01 Agents that bind IgE

Country Status (7)

Country Link
US (1) US8343504B2 (zh)
EP (1) EP1978990B1 (zh)
JP (1) JP5123858B2 (zh)
CN (1) CN101351216B (zh)
AT (1) ATE551065T1 (zh)
GB (1) GB0522298D0 (zh)
WO (1) WO2007051975A2 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5570996B2 (ja) 2007-12-14 2014-08-13 エアロデザインズ インコーポレイテッド エアロゾル化可能な食料品の送達
GB201203337D0 (en) 2012-02-24 2012-04-11 Natural Environment Res Council Method
CN110567787A (zh) * 2019-09-12 2019-12-13 浙江工商大学 一种快速纯化血清中IgG和IgE的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9406708D0 (en) * 1994-04-05 1994-05-25 Mallinckrodt Veterinary Inc Vaccines
ES2236807T3 (es) 1996-05-18 2005-07-16 Evolutec Limited Moleculas de union de aminas vasoactivas.
EP1254168A2 (en) * 2000-02-11 2002-11-06 Evolutec Limited Cytokine inhibittory molecules from tick salivary glands
WO2002094228A1 (en) * 2001-05-23 2002-11-28 David Follansbee Prevention and treatment of allergies by helminthic regulation of ige
GB0307544D0 (en) 2003-04-01 2003-05-07 Evolutec Ltd Treatment method
JP4809242B2 (ja) * 2003-12-24 2011-11-09 メルク セローノ ソシエテ アノニム 新規なｃｃ−ケモカイン結合タンパク質

Also Published As

Publication number Publication date
US8343504B2 (en) 2013-01-01
WO2007051975A3 (en) 2007-06-28
ATE551065T1 (de) 2012-04-15
JP2009519213A (ja) 2009-05-14
CN101351216B (zh) 2014-07-16
EP1978990A2 (en) 2008-10-15
CN101351216A (zh) 2009-01-21
WO2007051975A2 (en) 2007-05-10
JP5123858B2 (ja) 2013-01-23
US20080280828A1 (en) 2008-11-13
EP1978990B1 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
ATE527365T1 (de) Il-15r alpha -sushi domäne als selektiver und effizienter verstärker der il-15-wirkung durch il-15rbeta/gamma , in hyperagonist il-15 ralpha sushi -il 15 fusionsproteine .
EA016245B9 (ru) Антитела против альфа2-интегрина и их применение
EP2118123A4 (en) STABILIZED P53 PEPTIDES AND ITS USES
ATE481984T1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
WO2009009173A3 (en) Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
ATE529442T1 (de) Verbesserte humane interferon-moleküle und ihre verwendungen
TN2010000096A1 (en) Oxadiazole - and oxazole - substituted benzimidazole - and indole - derivatives as dgat1 inhibitors
NO20082240L (no) GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser
TW200732349A (en) Anti-OX40L antibodies and methods using same
ATE471334T1 (de) Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
WO2006118772A3 (en) Fcrn antibodies and uses thereof
MY170509A (en) Activin-actrii antagonists for use in treating anemia
WO2009013543A3 (en) Targeted binging agents directed to kdr and uses thereof - 035
WO2007079218A3 (en) Metalloproteinase binding proteins
PL1922128T3 (pl) Element do zmniejszania zawartości drobnego pyłu w powietrzu, za pomocą mchów i/lub porostów
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
DE602005018106D1 (de) En zur beurteilung des steuersystems und dafür verwendetes computerprogramm
MX2010004615A (es) Anticuerpos monoclonales contra proteina c. activada e inactivada.
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2005071067A3 (en) Non-animal origin stabilizers and processes for producing the same
GB0522298D0 (en) Agents that bind IgE

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)